ReviewThe international journal of neuropsychopharmacology2018
Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.
Review in The international journal of neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of traditional and deep learning methods for detecting depression based on speech features: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Adjunctive brexpiprazole in patients with unresolved symptoms of depression on antidepressant treatment who are early in the disease course: post hoc analysis of randomized controlled trials.The international journal of neuropsychopharmacology · 2025Trial
- QSAR-Guided Design of Serotonin Transporter Inhibitors Supported by Molecular Docking and Biased Molecular Dynamics.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy and safety of perospirone as adjunctive therapy in major depressive disorder patients with inadequate response to antidepressants: a randomized clinical trial.EClinicalMedicine · 2025Article
- A longitudinal analysis of the relationship between emotional symptoms and cognitive function in patients with major depressive disorder.Psychological medicine · 2025Article
- A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study.Advances in therapy · 2025Observational
- Urgency to treat and early optimized treatment in major depressive disorder: consequences of delayed treatment, barriers to implementation, and practical strategies for clinicians.CNS spectrums · 2025Review
- A survey of patient-physician communication regarding treatment prospects and goal setting in the management of major depressive disorder in Japan.BMC psychiatry · 2025Article
- Impact of Emotional Blunting on Patient Social Function and Depressive Symptoms: A Post Hoc Analysis of a Web-Based Survey in Japanese Patients with Major Depressive Disorder.Neuropsychiatric disease and treatment · 2025Article
- A web-based survey on the occurrence of emotional blunting in patients with major depressive disorder in Japan: Patient perceptions and attitudes.Neuropsychopharmacology reports · 2024Article
- Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA.Journal of comparative effectiveness research · 2024Observational
- Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.Journal of psychopharmacology (Oxford, England) · 2023Observational
- Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence.Journal of psychiatric and mental health nursing · 2023Review
- Residual symptoms and their associated factors among Thai patients with depression: a multihospital-based survey.Annals of general psychiatry · 2022Article
- Article
- Individualized antidepressant therapy in patients with major depressive disorder: Novel evidence-informed decision support tool.Canadian family physician Medecin de famille canadien · 2022Review
- Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.BMC psychiatry · 2022Article
- Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis.BMC psychiatry · 2022Article
- Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life.Annals of general psychiatry · 2022Article
- Emotional blunting in patients with depression. Part I: clinical characteristics.Annals of general psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder is an often chronic and recurring illness. Left untreated, major depressive disorder may result in progressive alterations in brain morphometry and circuit function. Recent findings, however, suggest that pharmacotherapy may halt and possibly reverse those effects. These findings, together with evidence that a delay in treatment is associated with poorer clinical outcomes, underscore the urgency of rapidly treating depression to full recovery. Early optimized treatment, using measurement-based care and customizing treatment to the individual patient, may afford the best possible outcomes for each patient. The aim of this article is to present recommendations for using a patient-centered approach to rapidly provide optimal pharmacological treatment to patients with major depressive disorder. Offering major depressive disorder treatment determined by individual patient characteristics (e.g., predominant symptoms, medical history, comorbidities), patient preferences and expectations, and, critically, their own definition of wellness provides the best opportunity for full functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.